HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

Carmen Criscitiello, Vincenzo Bagnardi, Giuseppe Viale, Davide Disalvatore, Nicole Rotmensz, Angela Esposito, Aron Goldhirsch, Giuseppe Curigliano

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.

Original languageEnglish
Pages (from-to)3537-3540
Number of pages4
JournalAnticancer Research
Volume36
Issue number7
Publication statusPublished - 2016

Keywords

  • Breast cancer
  • Equivocal HER2 status
  • HER2 amplification
  • Heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence'. Together they form a unique fingerprint.

Cite this